RedHill Biopharma Ltd., a specialty biopharmaceutical company, has signed a collaborative research agreement with Duke University School of Medicine outlining plans for multiple in vivo studies. The program is designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury, aimed at providing results sufficient to advance opaganib into further definitive U.S. government-sponsored development under the U.S. Food and Drug Administration’s (FDA) Animal Rule...